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more, regulatory requirements stipulate that a new orphan status application
must be submitted for each indication. Under EMA regulations, orphan and non-
orphan indications cannot be granted under the same marketing authorization.
Although expansions between orphan and non-orphan indications are more com-
mon in the US, no examples of expansion from a non-orphan to orphan indication
were identified by the authors. CONCLUSIONS: While indication expansion be-
tween orphan indications is relatively common, examples of expansion into or out
of orphan indications are less frequent due to the regulatory restrictions. Pricing
and reimbursement dynamics in all cases are reflective of the trade-offs between
price potential and population size across indications.
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OBJECTIVES: Korea introduced a new positive list system in 2007 together with a
price negotiation procedure. Importantly, these two systems are run by two differ-
ent, independent organizations, namely the Health Insurance Review & Assess-
ment Service (HIRA) and the National Health Insurance Corporation (NHIC). HIRA
reviews the cost-effectiveness data in submissions and makes listing decisions,
then NHIC takes over and sets the reimbursement price via negotiations with
manufacturers. The aim of this study is to compare the difference in price after
cost-effectiveness appraisal by HIRA and price negotiation by NHIC, and to analyze
the factors that NHIC has considered to determine the reimbursement price.
METHODS: All 35 submissions made to the NHIC between August 2007 and June
2008 were reviewed. 19 submissions concluded with agreement, 15 failed and one
case was suspended. In this review only 15 cases of successful negotiations were
included. The level of the reimbursement price compared to the submitted price for
both essential drugs and non-essential ones and factors affecting the final price
were analyzed.RESULTS:The discrepancy between reimbursement price and cost-
effective price was about 12.3311.44% on average. For 3 essential drugs, the price
level was almost equal to the submitted price whereas the average level was 84.94
11.21% of the cost-effective price for non-essential drugs. The major factors af-
fecting negotiations to determine the final price were narrowed down to total cost
of substitutes, the foreign price, and the pharmaceutical budget impact.
CONCLUSIONS: Our findings have demonstrated that drug pricing within the new
environment has been done independently of cost-effectiveness appraisal. The
payer has exhibited limited bargaining power for essential drugs. Overall, 87.67% of
the cost-effective price was accepted during price negotiations, and the total cost of
substitutes, foreign prices and pharmaceutical budget impact were considered
equally when fixing the reimbursement price. A limitation of this study is that the
result may not be generalized because of insufficient cases.
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OBJECTIVES: Primary research is often only conducted in a limited number of key
markets despite a product being launched across a wider range of countries. In
order to understand the implications of research findings across geographies, mar-
kets can be grouped by common underlying factors. METHODS: Market segmenta-
tion frameworks were developed based on key decision drivers which can be ap-
plied at different points in a product lifecycle. Within each framework, markets can
be segmented in up to two domains to distinguish segments. In-depth secondary
research was conducted in EU27 markets to understand key pricing, reimburse-
ment, access and uptake processes. Qualitative analysis of these findings permit-
ted us to place markets in the segmentation framework, allowing extrapolation of
findings across similar markets. RESULTS: Markets can be segmented in several
domains, depending on areas of interest for the research in question. For example,
in the case of peri-launch segmentation, most new pharmaceuticals aim to secure
optimal pricing and reimbursement – therefore an understanding of similarities
and differences in these areas are of greatest interest. Markets can be assessed in
terms of HTA data requirement, degree of centralization of decision making, pric-
ing regulations (fixed vs. ‘free’ pricing) or pricing decision drivers. This approach
was applied to understanding market similarities for a novel, hospital adminis-
tered product in a rare disease area. All 27 EU markets were segmented by level of
price regulation into three groups: price set by manufacturer, price set through
negotiation or strict price regulation. Understanding pricing drivers in each group
allowed results from primary research undertaken in only 6 of these markets to be
used by the manufacturer in all EU27 markets. CONCLUSIONS: Applying these
conceptual frameworks to drive market segmentation, key similarities and differ-
ences between markets can be used to extrapolate findings from primary market
research, or determine what strategic options are applicable to a given market.
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OBJECTIVES: In 1994, in French health care system, a supplement status for am-
bulatory reimbursement drugs, called “exception drugs”, was established. This
status enables to reimburse only specified indications of particularly costly drugs.
In this study we analyze what characteristics a drug should possess in order to be
considered as an exception drug. METHODS: Included in the study, were drugs
that had status of “exception drugs” as of April 2011. The clinical (actual benefit,
improvement of actual benefit) and economic (amount reimbursed by National
Health Insurance) characteristics were collected from official and publicly available
websources, as well as supplement restrictions for prescription (any prescription
or only the first one must be accomplished by a hospital practitioner; prescription
must be accomplished by a specialist; or prescription requires specific following
during the treatment). RESULTS: As of April 2011, there were 56 “exception drugs”
in trade name and 30 in generic name. The drugs from 9 ATC classes level I were
presented; the most numerous were A16 (Other alimentary tract and metabolism),
H01 (Pituitary and hypothalamic hormones and analogues), B03 (Antianemic prep-
arations). Supplement restrictions for prescription was applied to 33 drugs. Some
“exception drugs” (10) had also the status of drugs financed out of DRG payment
system. Most of the drugs, 91.07% (51/56) had high level of actual benefit. Around
half of the “exception drugs”, 42.86% (24/56) had level of improvement in actual
benefit from I to III. In 2009, part of reimbursed amount of “exception drugs” was
7.73% from all reimbursed drugs, whereas in 2004 it was 2.85%. Interestingly, in
2009 four exception drugs constituted about 1% of the reimbursed amount each,
and 40 – less than 0.1%. CONCLUSIONS: The analyzed types of characteristics, both
economic and clinical, can be used as criteria for establishing the status of excep-
tion drug.
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OBJECTIVES: Generic competition is an effective cost-containment mechanism
that improves static efficiency and stimulates pharmaceutical innovation. No prior
study has empirically analysed the relative delays in adoption of generic competi-
tion within the OECD. This study aims to investigate how price regulations in the
OECD affect timing of generic adoption following the first global generic launch.
METHODS: Drawing upon data from 1999 to 2008, we estimate the impact of ex-
ante price and market size expectations on the probability of generic launch using
discrete-time duration modeling with cloglog and logit regressions. The economet-
ric strategy employs both parametric and non-parametric duration dependence
and includes controls for local generic competition, firm characteristics and mol-
ecule heterogeneity. RESULTS: Ex-ante profit expectations result in faster adop-
tion; both expected price and market size increase the probability of launch. Our
findings suggest that neither molecule nor firm characteristics have a significant
effect on generic adoption across different specifications.CONCLUSIONS: Evidence
indicates that regulation has a significant impact on timing of adoption; however,
generic competitors tend to follow a locally oriented strategy in contrast to re-
search-intensive pharmaceutical firms.
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OBJECTIVES: Biosimilars are predicted to reduce prices of biologicals. Among bio-
similars, epoetin alfa has the largest market penetration in Germany and Spain.
The aim of this study was to describe the political, technological, economical and
social factors that impact on epoetin alfa sales and price in both European coun-
tries, which greatly differ in their generic market size. METHODS: Revisions of
regulatory legislation and policies regarding biosimilars at country and European
levels have been conducted. Estimations of market shares in units for epoetin alfa
originator and biosimilars plus darbopoetin alfa, a second generation biological,
were calculated. Epoetin alfa pricing trend was followed. All data was extracted
from IMS MIDAS database, using standard units and ex-manufacturer price.
RESULTS: Both countries are under the same regulatory framework and have pol-
icies that promote generic penetration, although automatic biosimilar substitution
is banned. Price of first launched biosimilar was approximately 30% below origina-
tor price in both countries. In Germany, originator price decreased about 16% after
launch of second biosimilar, whereas in Spain, originator price trend have no
changes to date. Regarding originator market shares, they did not change after
launch of biosimilars in Spain, while in Germany marked reductions were observed
along with biosimilars market share increases. In Spain, market shares of darbo-
poetin alfa were reduced when epoetin alfa biosimilar sales started, but no changes
of the kind were documented in Germany. CONCLUSIONS: Although both coun-
tries face similar political and technological factors; in Spain, social and economi-
cal ones could negatively impact stakeholder perception. In this country, the in-
troduction of biosimilars do not modify market share of the originator despite it
has a price about 30% higher. In Germany, stakeholders pose minimum resistance
to biosimilars, as market share and price of originator are immediately reduced
after the entry of biosimilars.
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OBJECTIVES:Most OECD countries employ pricing controls to contain rising health
care expenditures. The recent financial crisis has resulted in further pressure to
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enact more stringent price controls. The purpose of this study is to provide empir-
ical evidence on how price regulations in the OECD affected the adoption speed of
new patent-protected pharmaceutical technologies during 1999-2008. METHODS:
We use discrete time duration modelling with parametric and semi-parametric
duration dependence to examine how price expectations shape the probability of
launch, controlling for competition, market size expectations, firm and molecule
heterogeneity across the major OECD markets during 1999-2008. A sub-sample
analysis including only EU countries also investigates the impact of price interde-
pendencies and potential firm strategies in launch and pricing decisions. RESULTS:
The empirical analysis suggests there is a statistically significant and robust price
and market size effect in the adoption of new pharmaceutical technologies. A unit
increase in the log expected launch price and the log of expected market size
increases the probability of launch by 0.003 and 0.002 respectively. Concentrated
therapeutic subgroups, reflecting market crowding constitutes a significant barrier
to entry. Sub-sample findings from the EU market suggest strategic firm behaviour
with firms delaying launch in low-priced markets and attempts to maintain price
differentials across interdependent markets to a minimum due to price comple-
mentarities. Firm economies of scale and the therapeutic importance of innova-
tions are other important drivers of early adoption. CONCLUSIONS: A significant
and robust price and market size effect is observed in the likelihood of new phar-
maceutical adoption. Price regulations slow down pharmaceutical adoption on a
global scale and may impose welfare losses, particularly when the innovations that
are delayed are cost-effective from a societal perspective. Due to scale advantages
observed in international roll-out strategies, price controls may increase incentives
for mergers and acquisitions, further increasing concentration levels and barriers
to entry.
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OBJECTIVES: To understand the role of discounts/rebates impacting medicines
prices in hospitals. METHODS: Qualitative survey with competent authorities and
hospital pharmacists about purchasing strategies for hospital medicines with all
EU Member States and two further European countries (Norway, Turkey) Price
survey (study visits) of 12 active ingredients in 25 hospitals in Austria, the The
Netherlands, Norway, Portugal, Slovakia. RESULTS:Of a total of 27 European coun-
tries, 25 countries reported about the practice of discounts and/or rebates (ex-post
price reductions). The range of the discounts varied among the countries and with
regard to the products. Apart from Italy with mandatory discounts to the NHS,
discounts were always commercial and as such usually kept confidential. Free-cost
medicines (i.e. medicines provided without payment) were reported to be a prac-
tice in six countries, whereas it is legally forbidden in another six countries. In
Austria, the The Netherlands, Portugal, and Slovakia discounts were granted in
individual negotiations between suppliers and hospitals for some of the surveyed
products (e.g., for cardiovascular medicines where generics were available; how-
ever no discounts for all oncology medicines of the sample). In Norway, discounts
played no role since medicines were tendered centrally. In Austria and Slovakia
medicines were provided cost-free to some/all hospitals (only in the indication of
cardiovascular treatment). In Portugal, unit prices of nearly € 0.00 were surveyed
for a few cardiovascular medicines attributable to rebates. CONCLUSIONS: In the
in-patient sector, confidential discounts, and, to a lesser extent, rebates and cost-
free medicines are common in some countries. Discounts are more likely to be
provided where there are (off-patent) therapeutic alternatives available. Large dis-
counts and cost-free provision appear to be a practice for “strategic products”
which account for high volume and expenditure in the out-patient sector.
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OBJECTIVES: The increase in premium-priced orphan drugs coupled with health
care budget constraints will pressure managed care plans to consider restricting
market access. Coverage and reimbursement of ten FDA-designated orphan drugs
(ceramide, alglucerase, modafinil, lamotrigine, laronidase, nitisinone, alpha-gluco-
sidase, galsulfase, idursulfase, bosentan) were analyzed for ten popular Medicare
PDP (AARP, Cigna, CVS Caremark, Humana, Medco, RxAmerica, EmblemHealth,
UniCare, WellCare, FirstHealth.METHODS: Formulary tier structure, out-of-pocket
costs (OPC), monthly retail costs and utilization restrictions (UR)—pre-authoriza-
tion (PA), quantity limits (QL) and step therapy (ST)—were obtained from CMS
(www.medicare.gov). UR were assigned point values reflecting most to least re-
strictive—PA, 3; ST, 2; QL, 1; 6 possible points per drug per plan unless excluded
from formulary. OPC is the percentage of the drugs’ costs paid by patients—an
average of deductible, initial, gap, and catastrophic OPC. Disease incidences were
obtained from a variety of sources. RESULTS: Monthly retail prices ranged from
$19.56 (lamotrigine; generic) to $5,946.37 (bosentan). The drugs excluded from the
most formularies were alglucerase and myozyme (3 each). Lamotrigine, the least
expensive drug, had the highest OPC as a percentage of its retail price (57.58%) on
average among the plans; however, this may be because of its low retail price.
Bosentan had the lowest OPC (36.48%). There was no correlation between drug
price and UR points (r20.030). There were a slight positive correlation between
disease incidence and drug price (r20.219) and between disease incidence and
OPC (r20.380). There were slight negative correlations between a drug’s UR points
and its OPC percentage (r20.163) and between its retail price and OPC (r20.423).
CONCLUSIONS: URs on orphan drugs were prevalent in Medicare plans, with pa-
tients bearing 40-60% of the OPC. The extent of restrictions was not proportional to
the drugs’ price, suggesting that more research is warranted to investigate the
factors related to orphan drug access.
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OBJECTIVES: Pharmaceutical drug costs represent a large portion of government
health care spending. A national standard to regulate the process of public finan-
cial reimbursement for drugs does not exist in Canada and variations in practices
are evident across the country. The purpose of this study was to provide a compre-
hensive overview of how drug-funding decisions are made in Ontario. METHODS:
Access to Ontario’s Committee to Evaluate Drugs (CED) meeting minutes (July 2009-
July 2010) was granted. A data abstraction form was created based on the frame-
work established by Johnson et al. (2009). For each criterion, importance to the final
decision, strength of evidence and quality of evidence were recorded. Two review-
ers independently extracted the information and consensus was achieved.
RESULTS: Forty-four submissions were included. Five main observations: 1) the
CED considered certain criteria more frequently than others (e.g., clinical benefit
was considered for all decisions, while societal values were discussed less fre-
quently); 2) the relative impact of each criterion on the CED’s recommendation
varied (e.g., overall clinical benefit, efficacy, value for money, and need had the
largest influence); 3) the CED was more likely to discuss the strength of evidence
when its recommendation did not support public funding (e.g., the strength of cost
evidence was discussed 3 times more often for those drugs not recommended for
funding); 4) the frequency with which the CED considered criteria varied according
to whether or not the CED believed there was an established need; and 5) the
majority of the comments made by the CED about the strength of evidence indi-
cated that the quality of the data was low. CONCLUSIONS: This review identified
trends in the influence of different criteria involved in the CED’s drug assessment
process. These results may promote the development and application of a com-
prehensive, consistent, and transparent framework for reimbursement decision-
making.
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BACKGROUND: Pharmaceutical consultation (PC) aims to maximize the successful
outcome of a drug treatment. Although its benefits are well documented, several
different PC models are implemented in various healthcare settings (HCS) and no
optimal model has been identified. OBJECTIVES: To analyze the characteristics of
PC models most relevant to key clinical, monetary, and social objectives, and to
design PC models that optimize them and could be implemented in various HCS
and in primary care in Israel. METHODS:We systematically reviewed studies of PC
programs published from 2000–2010. We analyzed the programs by their organi-
zational characteristics and defined a scale for measuring their success that incor-
porated the clinical, monetary and social objectives. Their results were then scored
accordingly. We calculated the association between each of the key organizational
characteristics and the success score to identify the characteristics that maximize
the program’s success. RESULTS: The analysis revealed three core patterns: con-
sultation to patient and physician, patient alone, and physician alone. For each
pattern, three feasible models for optimal PC were found. The organizational char-
acteristics of each model included the subject and location of the consultation,
target population, consultant’s profession, communication method, incentives,
duration, financing, and the PC process steps. CONCLUSIONS: This method for
optimizing a model for PC program could be implemented in a variety of HCS to
maximize successful drug treatment reflected in the prevention and control of
illnesses, improved clinical outcomes, enhanced well-being of the population and
maximum economic benefits. Interviews with a sample of key players in HCS could
reveal preferences and benefits, which then will be combined with the results of
the previous analysis to optimize a PC program for primary care in Israel and for
other HCS.
PHP26
HEALTH OUTCOMES AND ECONOMICS RESEARCH FOR REGENERATIVE
MEDICINE AND CELLULAR THERAPIES: LESSONS FROM A MULTI-MARKET
HEALTH TECHNOLOGY ASSESSMENT AND REIMBURSEMENT REVIEW
Faulkner EC1, Fernandez M2, Spinner DS1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, RTP, NC, USA
OBJECTIVES: Regenerative medicines, which include cellular and gene therapies,
offer to shift the focus of healthcare from one of palliative care to curative treat-
ment. Because these technologies are novel, more complex than standard biophar-
maceuticals, and often costly, they are anticipated to face heavy scrutiny for mar-
ket access and adoption. The objective of this analysis was to evaluate published
HTAs and reimbursement policies on regenerative medicines for select global mar-
kets, compare them to existing biopharmaceuticals, and evaluate lessons for HEOR
and market access planning. METHODS: A search of HTAs and reimbursement
policies from Australia, Canada, France, Germany, Sweden, the UK (UK) and the
United States (US) was conducted to identify reimbursement recommendations
and key HEOR considerations for this new field. A review of the literature, including
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